123 related articles for article (PubMed ID: 20501999)
1. Small molecule inhibitors of acid sphingomyelinase.
Arenz C
Cell Physiol Biochem; 2010; 26(1):1-8. PubMed ID: 20501999
[TBL] [Abstract][Full Text] [Related]
2. Sphingomyelin analogues as inhibitors of sphingomyelinase.
Taguchi M; Sugimoto K; Goda K; Akama T; Yamamoto K; Suzuki T; Tomishima Y; Nishiguchi M; Arai K; Takahashi K; Kobori T
Bioorg Med Chem Lett; 2003 Jun; 13(12):1963-6. PubMed ID: 12781174
[TBL] [Abstract][Full Text] [Related]
3. Influence of the scyphostatin side chain on the mode of inhibition of neutral sphingomyelinase.
Wascholowski V; Giannis A; Pitsinos EN
ChemMedChem; 2006 Jul; 1(7):718-21. PubMed ID: 16902925
[No Abstract] [Full Text] [Related]
4. Functional Inhibitors of Acid Sphingomyelinase (FIASMAs): a novel pharmacological group of drugs with broad clinical applications.
Kornhuber J; Tripal P; Reichel M; Mühle C; Rhein C; Muehlbacher M; Groemer TW; Gulbins E
Cell Physiol Biochem; 2010; 26(1):9-20. PubMed ID: 20502000
[TBL] [Abstract][Full Text] [Related]
5. Phosphatidylinositol-3,5-Bisphosphate is a potent and selective inhibitor of acid sphingomyelinase.
Kölzer M; Arenz C; Ferlinz K; Werth N; Schulze H; Klingenstein R; Sandhoff K
Biol Chem; 2003 Sep; 384(9):1293-8. PubMed ID: 14515991
[TBL] [Abstract][Full Text] [Related]
6. Functional inhibitors of acid sphingomyelinase (FIASMAs).
Kornhuber J; Tripal P; Gulbins E; Muehlbacher M
Handb Exp Pharmacol; 2013; (215):169-86. PubMed ID: 23579455
[TBL] [Abstract][Full Text] [Related]
7. Acid sphingomyelinase inhibitors normalize pulmonary ceramide and inflammation in cystic fibrosis.
Becker KA; Riethmüller J; Lüth A; Döring G; Kleuser B; Gulbins E
Am J Respir Cell Mol Biol; 2010 Jun; 42(6):716-24. PubMed ID: 19635928
[TBL] [Abstract][Full Text] [Related]
8. [Correction of age-related changes in sphingolipid content in rat tissues by acid sphingomyelinase inhibition].
Har'kavenko VV; Storozhenko GB; Krasnikova OM; Babenko NO
Fiziol Zh (1994); 2012; 58(1):56-60. PubMed ID: 22590738
[TBL] [Abstract][Full Text] [Related]
9. Potent inhibition of acid sphingomyelinase by phosphoinositide analogues.
Roth AG; Redmer S; Arenz C
Chembiochem; 2009 Sep; 10(14):2367-74. PubMed ID: 19688786
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Acid Sphingomyelinase Depletes Cellular Phosphatidylserine and Mislocalizes K-Ras from the Plasma Membrane.
Cho KJ; van der Hoeven D; Zhou Y; Maekawa M; Ma X; Chen W; Fairn GD; Hancock JF
Mol Cell Biol; 2016 Jan; 36(2):363-74. PubMed ID: 26572827
[TBL] [Abstract][Full Text] [Related]
11. Permeability barrier disorder in Niemann-Pick disease: sphingomyelin-ceramide processing required for normal barrier homeostasis.
Schmuth M; Man MQ; Weber F; Gao W; Feingold KR; Fritsch P; Elias PM; Holleran WM
J Invest Dermatol; 2000 Sep; 115(3):459-66. PubMed ID: 10951284
[TBL] [Abstract][Full Text] [Related]
12. Gentamicin Targets Acid Sphingomyelinase in Cancer: The Case of the Human Gastric Cancer NCI-N87 Cells.
Albi E; Cataldi S; Ceccarini MR; Conte C; Ferri I; Fettucciari K; Patria FF; Beccari T; Codini M
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31489901
[TBL] [Abstract][Full Text] [Related]
13. Novel inhibition mechanism of Bacillus cereus sphingomyelinase by beryllium fluoride.
Fujii S; Nagata M; Morita M; Minoura K; Tsukamoto K; Ikezawa H; Ikeda K
Arch Biochem Biophys; 2004 Apr; 424(2):201-9. PubMed ID: 15047192
[TBL] [Abstract][Full Text] [Related]
14. Discovery of N-hydroxy-3-alkoxybenzamides as direct acid sphingomyelinase inhibitors using a ligand-based pharmacophore model.
Yang K; Nong K; Gu Q; Dong J; Wang J
Eur J Med Chem; 2018 May; 151():389-400. PubMed ID: 29649738
[TBL] [Abstract][Full Text] [Related]
15. Plasma membrane reorganization links acid sphingomyelinase/ceramide to p38 MAPK pathways in endothelial cells apoptosis.
Niaudet C; Bonnaud S; Guillonneau M; Gouard S; Gaugler MH; Dutoit S; Ripoche N; Dubois N; Trichet V; Corre I; Paris F
Cell Signal; 2017 May; 33():10-21. PubMed ID: 28179144
[TBL] [Abstract][Full Text] [Related]
16. Potent and selective inhibition of acid sphingomyelinase by bisphosphonates.
Roth AG; Drescher D; Yang Y; Redmer S; Uhlig S; Arenz C
Angew Chem Int Ed Engl; 2009; 48(41):7560-3. PubMed ID: 19746379
[No Abstract] [Full Text] [Related]
17. Cationic cell-penetrating peptides induce ceramide formation via acid sphingomyelinase: implications for uptake.
Verdurmen WP; Thanos M; Ruttekolk IR; Gulbins E; Brock R
J Control Release; 2010 Oct; 147(2):171-9. PubMed ID: 20620184
[TBL] [Abstract][Full Text] [Related]
18. The role of acidic amino-acid residues in catalytic and adsorptive sites of Bacillus cereus sphingomyelinase.
Tomita M; Ueda Y; Tamura H; Taguchi R; Ikezawa H
Biochim Biophys Acta; 1993 Nov; 1203(1):85-92. PubMed ID: 8218395
[TBL] [Abstract][Full Text] [Related]
19. A photocaged inhibitor of acid sphingomyelinase.
Prause K; Naseri G; Schumacher F; Kappe C; Kleuser B; Arenz C
Chem Commun (Camb); 2020 Nov; 56(94):14885-14888. PubMed ID: 33179626
[TBL] [Abstract][Full Text] [Related]
20. Acid Sphingomyelinase Inhibition Stabilizes Hepatic Ceramide Content and Improves Hepatic Biotransformation Capacity in a Murine Model of Polymicrobial Sepsis.
Chung HY; Witt CJ; Hurtado-Oliveros J; Wickel J; Gräler MH; Lupp A; Claus RA
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30326559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
